Receptor Partners
Receptor Partners is a venture capital firm established in 2017 and located in New York, New York. The firm focuses on investing in early and mid-stage drug discovery companies within the psychedelic medicine sector. Recognizing the potential of psychedelics to revolutionize the treatment landscape for various mental health disorders, including depression, addiction, PTSD, and anxiety, Receptor Partners aims to support the development of innovative therapies that can address these significant global health challenges.
Mycrodose Therapeutics is a US-Based pharmaceutical company specialized in the development of advanced drug delivery (ADD) systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. The company is in the parallel development of two of its four core technologies; a psilocybin transdermal delivery system, Ketamine oral mucosa delivery system.
Mindstate Design Labs is a clinical-stage biotechnology company developing the next generation of psychedelic-inspired therapeutics for intractable mental health conditions. The company maps the biological basis of the varieties of psychedelic experiences and uses that map to design psychoactive effects to be applied in medically supervised settings to heal the root causes of mental health disorders.
Psilera is a biopharmaceutical company focused on developing groundbreaking therapeutics for neurodegenerative diseases by creating a new class of neurological medicines. Psilera's lead asset, PSIL-006, is a non-hallucinogenic psilocybin derivative for the treatment of frontotemporal dementia (FTD). With a deep commitment to improving the patient experience through scientific excellence, Psilera is transforming the lives of individuals affected by devastating diseases. Welcome to the new era of mindful medicine.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.